✦ LIBER ✦

Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer

✍ Scribed by Lawrence N. Shulman; Lori Buswell; Howard Goodman; Michael Muto; Ross Berkowitz; Beverly Teicher; Tetsuya Kusumoto; Selwyn J. Hurwitz; Leslie A. Kalish; C. Norman Coleman

Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 471 KB
Volume: 29
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(94)90453-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of the hypoxic cell sensitizer etani

Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: A pharmacokinetic study

✍ Lawrence N. Shulman; Lori Buswell; Leslie A. Kalish; C. Norman Coleman 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 422 KB

RTOG #89-06: A phase I study to evaluate

RTOG #89-06: A phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies

✍ Francine E. Halberg; Dennis Cosmatis; Leonard L. Gunderson; R. Dirk Noyes; Geral 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 773 KB

Phase II study of pemetrexed in combinat

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; Georg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 3 views

Phase II study of belotecan, a camptothe

Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

✍ Chel Hun Choi; Yoo-Young Lee; Tae-Jong Song; Hwang-Shin Park; Min Kyu Kim; Tae-J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Dose intensive combination platinum and

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

✍ Jeremy D. Shapiro; Mace L. Rothenberg; Gisele A. Sarosy; Seth M. Steinberg; Debr 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## BACKGROUND. The authors combined cisplatin and carboplatin together with cyclophosphamide to maximize platinum dose intensity in patients with advanced epithelial ovarian cancer (AOC). ## METHODS. The authors treated 26 consecutive, newly diagnosed patients with International Federation of G

Phase I/II study of carboplatin and oral

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer

✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-